BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34117374)

  • 21. Cyclosporin A induces erythroid differentiation of K562 cells through p38 MAPK and ERK pathways.
    Sawafuji K; Miyakawa Y; Kizaki M; Ikeda Y
    Am J Hematol; 2003 Jan; 72(1):67-9. PubMed ID: 12508271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ERK signaling pathway is differentially involved in erythroid differentiation of K562 cells depending on time and the inducing agent.
    Woessmann W; Zwanzger D; Borkhardt A
    Cell Biol Int; 2004; 28(5):403-10. PubMed ID: 15193284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2.
    Ren JG; Seth P; Everett P; Clish CB; Sukhatme VP
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levels of Smad7 regulate Smad and mitogen activated kinases (MAPKs) signaling and controls erythroid and megakaryocytic differentiation of erythroleukemia cells.
    Akel S; Bertolette D; Petrow-Sadowski C; Ruscetti FW
    Platelets; 2007 Dec; 18(8):566-78. PubMed ID: 18041647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
    Grüllich C
    Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activin A induces erythroid gene expressions and inhibits mitogenic cytokine-mediated K562 colony formation by activating p38 MAPK.
    Huang HM; Chiou HY; Chang JL
    J Cell Biochem; 2006 Jul; 98(4):789-97. PubMed ID: 16440334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.
    Elf S; Blevins D; Jin L; Chung TW; Williams IR; Lee BH; Lin JX; Leonard WJ; Taunton J; Khoury HJ; Kang S
    Blood; 2011 Jun; 117(25):6885-94. PubMed ID: 21527514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
    Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
    Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclic nucleotide response element binding (CREB) protein activation is involved in K562 erythroleukemia cells differentiation.
    Di Pietro R; di Giacomo V; Caravatta L; Sancilio S; Rana RA; Cataldi A
    J Cell Biochem; 2007 Mar; 100(4):1070-9. PubMed ID: 17063485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plastrum testudinis induces γ-globin gene expression through epigenetic histone modifications within the γ-globin gene promoter via activation of the p38 MAPK signaling pathway.
    Qian X; Chen J; Zhao D; Guo L; Qian X
    Int J Mol Med; 2013 Jun; 31(6):1418-28. PubMed ID: 23588991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of ERK activation in growth and erythroid differentiation of K562 cells.
    Woessmann W; Mivechi NF
    Exp Cell Res; 2001 Apr; 264(2):193-200. PubMed ID: 11262176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
    Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
    Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radicicol-mediated inhibition of Bcr-Abl in K562 cells induced p38-MAPK dependent erythroid differentiation and PU.1 down-regulation.
    Morceau F; Buck I; Dicato M; Diederich M
    Biofactors; 2008; 34(4):313-29. PubMed ID: 19850986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythroid differentiation is augmented in Reelin-deficient K562 cells and homozygous reeler mice.
    Chu HC; Lee HY; Huang YS; Tseng WL; Yen CJ; Cheng JC; Tseng CP
    FEBS Lett; 2014 Jan; 588(1):58-64. PubMed ID: 24239537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
    Yang X; Liu L; Sternberg D; Tang L; Galinsky I; DeAngelo D; Stone R
    Cancer Res; 2005 Aug; 65(16):7338-47. PubMed ID: 16103085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activin A induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib.
    Huang YW; Lee WH; Tsai YH; Huang HM
    Am J Physiol Cell Physiol; 2014 Jan; 306(1):C37-44. PubMed ID: 24088895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
    Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Lin DW; Corey E; Nelson PS; Morrissey C
    PLoS One; 2021; 16(1):e0245602. PubMed ID: 33471819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3.
    Fukuda S; Singh P; Moh A; Abe M; Conway EM; Boswell HS; Yamaguchi S; Fu XY; Pelus LM
    Blood; 2009 Jul; 114(2):394-403. PubMed ID: 19411632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
    Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
    Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.